Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | UTRN | P46939 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12229789 | 0.85 | ALDH1A1 (0.34) | ALDH1A1UTRN | |
| SCHEMBL4148573 | 0.83 | POLB (0.39) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL12229747 | 0.83 | MEN1 (0.34) | MEN1KMT2APOLBTDP1NPSR1 | |
| SCHEMBL12229691 | 0.76 | MEN1 (0.47) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL12229721 | 0.76 | TDP1 (0.38) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL12229748 | 0.76 | POLB (0.34) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL12229713 | 0.73 | LMNA (0.40) | MEN1KMT2APOLBALDH1A1UTRN | |
| SCHEMBL12252174 | 0.72 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL578222 | 0.71 | POLB (0.38) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL27660907 | 0.70 | NPSR1 (0.47) | MEN1KMT2APOLBALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044091-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDENIX PHARMACEUTICALS LLC | 2009-06-25 | — | — | US | disclosed |
| US-7534809-B2 | Phospho-indoles as HIV inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163444-A1 | PHOSPHO-INDOLES AS HIV INHIBITORS | IDO1, PPP5C, INMT | MEN1 3483/4885KMT2A 1767/4885POLB 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.